&w=3840&q=100)
How to trade HDFC Bank stock ahead of bonus issue meet? Key levels to track
Rex Cano Mumbai
Listen to This Article
HDFC Bank stock is likely to be in focus in the run-up to the July 19 (Saturday) meeting; wherein the bank's board will be announcing the Q1 results, and also consider the proposal for a special dividend and its first-ever bonus share issue. On Wednesday, HDFC Bank stock rose to an intra-day high of ₹2,023 on the NSE, and quoted with a gain of around 0.6 per cent above the ₹2,000-mark in morning trade. The stock, at present, trades near life-time highs, and has surged as much as 25 per cent from the calendar year low
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
an hour ago
- Indian Express
Share price under Rs 200: Multibagger railway stock secured over Rs 1600 crore order last week
Multibagger railway stock order win: A multibagger railway PSU stock secured back-to-back orders last week, according to exchange filings. The total value of these new contracts exceeds Rs 1,600 crore. Can you guess which one? Here's a hint – as of July 20 (NSE data), this railway company has a market capitalisation of Rs 17,563.19 crore. This railway company is none other than IRCON International Limited. IRCON is a navratna company under the Ministry of Railways. Last week (July 14-18), IRCON bagged three new orders. These are as follows: In an exchange filing on July 18, the company said, 'Mumbai Metropolitan Region Development Authority has awarded the work to Ircon International Limited for CA-233, Line-6, Package-2: Design, Manufacture, Supply, Installation, Integration, Testing and Commissioning of Power Supply and Traction, E & M, Lifts & Escalators including 5 Years of Comprehensive Maintenance after 2 Years of Defect Liability Maintenance Period of Line 6 [Swami Samarth Nagar to Vikhroli (EEH)] of Mumbai Metro Rail Project of MMRDA.' The project cost is Rs 642,44,02,451.34. In a separate filing, the railway company said, ' Mumbai Metropolitan Region Development Authority has awarded the work to Ircon International Limited for CA-239, Line-5, Package-2: Design, Manufacture, Supply, Installation, Integration, Testing And Commissioning of 220 kV receiving Substation Including 220 kV, 33kV & 25kV Cabling Work, Complete 25kV Overhead Catenary System along with switching station, 33kV Auxiliary Power Distribution System Including 33/0.415 kV Auxiliary Sub-Station (ASS) And Complete SCADA System, Electrical and Mechanical works, Lift & Escalator Works for part of Main Line, Stations & Kasheli Depot of Mumbai Metro Rail Line 5 Project of MMRDA Including 5 Years of Comprehensive Maintenance after 2 Years of Defect Liability and Maintenance Period.' The project cost is Rs 471,29,72,820. In a filing on Friday, the company said, ' IRCON has been awarded with Letter of Award for the project floated by RVNL (Participated in this bid in JV mode with M/s JPWIPL (i.e., IRCON – 70% & JPIWL – 30%).' Here the total project amount is Rs 755,78,21,993.63 (IRCON Share – Rs 529,04,75,395.53),' the company said. Shares of IRCON closed in red on Friday (July 18). The PSU railway stock settled at Rs 186.74 apiece, down 1.60 per cent on NSE. IRCON International Limited is a component of the BSE 500. According to the BSE analytics (as of July 20), shares of IRCON gave negative returns in the last 1 week and 2 weeks, by 2.20 per cent and 6.27 per cent, respectively. Shares of the PSU railway stock also fell in the last 1 year by 40.25 per cent. However, in the past 2 years, 3 years, and 5 years, shares of the company rose 116.15 per cent, 405.27 per cent, and 307.03 per cent, respectively. This year, IRCON paid a dividend of Rs 1.65 in February. Last year, the PSU railway stock declared total dividends of Rs 3.10. IRCON issued bonuses in the ratio of 1:1 for the equity shareholders.
Economic Times
an hour ago
- Economic Times
Anthem Biosciences IPO: What GMP signals ahead of listing on Monday
Anthem Biosciences is set to debut on the stock exchanges on Monday, July 21. In the unlisted market, its shares are trading at a premium of Rs 165–170, indicating a potential listing gain of around 29% over the IPO price of Rs 570 (upper band). ADVERTISEMENT While the grey market premium (GMP) reflects strong investor interest, it remains a speculative indicator and can change quickly before listing. The Rs 3,395 crore IPO was entirely an offer for sale (OFS) and closed on July 16. It witnessed robust demand, with an overall subscription of 67.42 times. The Qualified Institutional Buyers (QIB) segment was subscribed 192.80 times, Non-Institutional Investors (NII) 44.70 times, and the retail portion 5.98 times. The issue was priced in a band of Rs 540–570 per share, with a minimum lot size of 26 shares. The stock will list on both NSE and BSE. Founded in 2006, Anthem Biosciences operates in a niche segment of the pharma value chain, offering end-to-end drug discovery, development, and manufacturing services. It is among the few Indian CRDMOs with integrated capabilities across both small molecules (chemical-based) and large molecules (biologics).Its differentiated fee-for-service (FFS) model has enabled it to cater to small and mid-sized biotech firms globally, which constitute a large portion of its client base. Since its inception, the company has served over 675 clients and completed more than 8,000 projects. ADVERTISEMENT In FY25, Anthem reported strong financials, with an EBITDA margin of 36.8% and a Return on Net Worth (RoNW) of 20.8%. As of March 2025, the company's net worth stood at Rs 2,410 facilities are cGMP-compliant and approved by global regulatory bodies such as the USFDA, ANVISA, TGA, and PMDA. The company is currently expanding its fermentation and synthesis capacities to meet growing demand for complex biologics and specialty ingredients. ADVERTISEMENT JM Financial is the book-running lead manager of the Anthem Biosciences IPO, while Kfin Technologies is the registrar for the issue. (Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
Indian Express
3 hours ago
- Indian Express
IPO Listing on July 21: Anthem Biosciences to debut on NSE, BSE
IPO Listing on July 21: Anthem Biosciences Limited will make its debut on NSE (National Stock Exchange) and BSE (Bombay Stock Exchange) on Monday, July 21. Anthem Biosciences IPO allotment finalised last week. The three-day subscription for Anthem Biosciences IPO was opened on July 14 (Monday) and closed on July 16 (Wednesday). On the closing day of the bidding, the initial public offer of Anthem Biosciences Ltd subscribed 63.86 times. The initial share sale received bids for 2,81,44,34,740 shares against 4,40,70,682 shares on offer, according to NSE data. The portion for qualified institutional buyers (QIBs) fetched a whopping 182.65 times subscription. The non-institutional investors part got subscribed 42.35 times, and retail individual investors (RIIs) received a 5.64 times subscription. Anthem Biosciences IPO has fixed the price band at Rs 540 to Rs 570 per equity share. KFin Technologies Limited is the registrar of Anthem Biosciences IPO. The face value and tick size of Anthem Biosciences IPO is Rs 2 and Re 1, respectively. Anthem Biosciences Limited's shares are proposed to be listed on NSE, and BSE. The listing will likely take place on July 21. JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited are the book running lead managers for the Anthem Biosciences IPO. HDFC Bank Limited and ICICI Bank Limited are the sponsor banks for the Anthem Biosciences IPO. Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It also manufactures and sells complex, specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. (With inputs from PTI)
